Paper: Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

Exciting additional f/u data of sequential Pembro followed by AVD for front line cHL, though only 30 patients treated, CMR after second cycle of AVD was 100%, the PFS and OS at median follow up of 33 months was 100%!

Read the full article here

Related Articles